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Conclusion: The results indicate the feasibility of VMAT 
treatments under tumor tracking for selected patients. The 
arcs available for planning influence the quality of 
treatment. The L partial arc plans had clinically acceptable 
quality in four patients. Treatments with reduced margins 
could be safely delivered by gating the treatment beam if the 
tumor motion exceeds the margins. Also, a great advantage is 
that the dose delivered to the tumor could be exactly 
monitored. 
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Purpose or Objective: Pancreatic cancer with vascular 
involvement has a poor prognosis regardless of treatment. 
The toxicity of chemoradiation to adjacent normal organs can 
contribute to treatment discontinuation and adverse 
outcomes in some patients. We hypothesized that real-time 
MRI guided radiotherapy for borderline or locally advanced 
pancreatic carcinoma would enable safer treatment delivery 
with tight margins and diminished normal tissue toxicity than 
conventional treatment approaches. 
 
Material and Methods: Patients with borderline or locally 
advanced pancreatic cancer were eligible for evaluation for 
MRI-guided radiotherapy. Patients underwent complete 
staging, including baseline CA19-9 and triple phase CT 
imaging. Patients underwent simulation with an inhale breath 
hold 3D and cine scans on a MRI Guided Treatment Planning 
system. Locoregional lymph node coverage was incorporated 
at the discretion of the Radiation Oncologist. The mean CTV 
to PTV expansion was 3 mm (range 2-5 mm). The primary 
GTV was tracked in real-time throughout treatment and the 
PTV or similar structure was used as a boundary for triggering 
treatment. A patient initiated repeated breath hold strategy 
was used to increase the reproducibility and duty cycle of 
radiotherapy. 
 
Results: We have completed treatment for our first 5 
patients with borderline or locally advanced pancreatic 
adenocarcinoma. The population was 4:1 Male:Female with a 
mean age of 61.8 years (range 52-67). All patients had an 
elevated CA19-9 at presentation, with a mean of 714 U/mL 
(range 62 – 2350 U/mL). Locoregional lymphatics were 
treated in 4/5 patients. The mean PTV was 222.7 cc (range 
40.3-346.4 cc). The PTV was treated to 50.4 Gy at 1.8 Gy per 
a fraction with concurrent chemotherapy for all patients. 
With a median follow-up of 166 days (range 50 – 278 days), an 
average 66% reduction in CA19-9 1-2 months following 
chemoradiation was observed. The OS is 60% at time of 
follow up. One grade 4 toxicity was observed with duodenal 
ulceration during radiotherapy requiring hospitalization. The 
number of patients, overall survival, local control, 
progression free survival, and changes in CA19-9 levels will be 
updated at the time of presentation. 
 
Conclusion: Real-time MRI-guided radiotherapy enables the 
design and delivery of highly conformal treatment for 
patients with borderline or locally advanced pancreatic 
carcinoma. A significant reduction in CA19-9 levels after 
treatment was observed. Real time MR imaging throughout 
treatment enables high precision tracking to minimize 
treatment margins and normal tissue dose exposure. MRI-
guided radiotherapy may provide opportunities for normal 
organ toxicity reduction and future dose escalation 
strategies. 
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Purpose or Objective: Thedevelopment of radiotherapy 
treatment units with integrated MRI scanners isstimulating 
interest in fully MRI-guided treatment protocols. Cine-
MRIsequences capable of acquiring 5-6 2D images per second 
are already available,thus providing a potential means of 
non-invasive, online motion monitoring withhigh soft-tissue 
contrast. This work investigates the feasibility of livermotion 
tracking using optical flow registration of Cine-MR images 
series. 
 
Material and Methods: Livercine-MRI series (balanced steady-
state free precession, 256x256 pixel, 1.28x1.28mm spacing, f 
= 3.3Hz) providing 220 images over a 70s scan were acquired 
in 25patients and 5 healthy volunteers after informed 
consent. Ground-truth livermotion consisted in the 
trajectories of numerous sparse features (PSIFT) extracted 
using apreviously tested algorithm based on the Scale 
Invariant Feature Transform(SIFT) [1]. For each subject, 
optical flow (OF) registration, as proposed in [2],was applied 
between the first image of the series and each subsequent 
frame,thus obtaining time-resolved dense motion fields [Fig. 
1]. Trajectories basedon OF (POF) were then derivedby 
applying these motion fields to the positions of the SIFT 
features detectedin the first image. To assess the accuracy of 
the motion fields, the 2D frame-by-framedistances (DSIFT-
OF)between PSIFT and POF were calculated forevery trajectory 
and, for each subject, their distributions were described 
withmedian, inter-quartile range, 5th and 95th 
percentiles.Linear correlation coefficients (rSIFT-OF) between 
